Key Points
- Insider Frank Torti sold 587,390 Roivant shares on Feb. 23 at an average $27.51 for $16.16M and had also sold 1.4M (Feb. 19) and 1,012,610 (Feb. 20) shares, trimming his position by 4.10% to 13,736,547 shares; the trades were disclosed in an SEC filing.
- Roivant stock was trading up about 2.2% and near its 12‑month high (around $27.76–$27.94) with a market cap of roughly $19.9B; analysts have a consensus rating of Moderate Buy and a $28.69 price target, while several firms have raised targets to the $33–$35 range.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Frank Torti sold 587,390 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $27.51, for a total transaction of $16,159,098.90. Following the completion of the sale, the insider owned 13,736,547 shares of the company's stock, valued at approximately $377,892,407.97. This trade represents a 4.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Frank Torti also recently made the following trade(s):
- On Thursday, February 19th, Frank Torti sold 1,400,000 shares of Roivant Sciences stock. The stock was sold at an average price of $27.42, for a total value of $38,388,000.00.
- On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The shares were sold at an average price of $27.15, for a total value of $27,492,361.50.
Roivant Sciences Trading Up 2.2%
Shares of ROIV opened at $27.76 on Tuesday. The stock has a 50 day moving average of $23.44 and a 200 day moving average of $19.07. The company has a market capitalization of $19.87 billion, a price-to-earnings ratio of -23.73 and a beta of 1.22. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $27.94.
Institutional Trading of Roivant Sciences
Institutional investors have recently modified their holdings of the business. Penn Davis Mcfarland Inc. raised its holdings in Roivant Sciences by 10.1% during the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company's stock valued at $28,173,000 after acquiring an additional 170,456 shares during the period. Valeo Financial Advisors LLC purchased a new position in shares of Roivant Sciences in the second quarter valued at $1,145,000. IFG Advisory LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $255,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $3,064,000. Finally, Franklin Resources Inc. purchased a new stake in Roivant Sciences during the 2nd quarter worth about $997,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a research note on Saturday, February 7th. Wall Street Zen upgraded shares of Roivant Sciences from a "strong sell" rating to a "hold" rating in a report on Sunday, November 16th. The Goldman Sachs Group boosted their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a "buy" rating in a research note on Monday, December 15th. HC Wainwright raised their price target on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a "buy" rating in a research note on Tuesday, February 10th. Finally, Citigroup upped their price objective on Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $28.69.
Read Our Latest Stock Report on ROIV
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
